Clinical Trials Directory

Trials / Unknown

UnknownNCT04421469

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

A Single-arm, Open Multicenter Phase II Clinical Study of Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
39 (estimated)
Sponsor
Fujian Cancer Hospital · Other Government
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and tolerability of JS001 and chemotherapy combined with local treatment in patients with multiple metastatic nasopharyngeal carcinoma.

Conditions

Interventions

TypeNameDescription
DRUGTriprilimab(JS001)1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed; 2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation); 3. JS001 maintenance treatment.

Timeline

Start date
2020-06-15
Primary completion
2023-04-15
Completion
2023-06-15
First posted
2020-06-09
Last updated
2020-06-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04421469. Inclusion in this directory is not an endorsement.